SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): July 29, 2008
Emergent BioSolutions Inc.
(Exact Name of Registrant as Specified in Charter)
(State or Other Jurisdiction
|2273 Research Boulevard, Suite 400, Rockville, Maryland
(Address of Principal Executive Offices)
Registrants telephone number, including area code: (301) 795-1800
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
Item 1.02. Termination of a Material Definitive Agreement.
On July 21, 2008, Protein Sciences Corporation (PSC) sent a letter to Emergent BioSolutions Inc.
(Emergent) purporting to terminate that Asset Purchase Agreement (the Agreement) dated May 26,
2008 among PSC, Emergent and Emergent Manufacturing Operations Meriden LLC, a wholly-owned
subsidiary of Emergent. Pursuant to the Agreement, Emergent agreed to acquire, and PSC agreed to
sell, substantially all of the assets of PSC, including FluBlok®, a Phase III recombinant influenza
vaccine candidate, PSCs interest in a manufacturing facility located in Meriden, Connecticut,
PSCs baculovirus expression vector system (BEVS) technology and PSCs other product candidates
based on the BEVS platform. The Agreement is described in more detail in a Current Report on Form
8-K filed by Emergent with the Securities and Exchange Commission on May 29, 2008. Additionally,
in connection with the entry into the Agreement, we have entered into a loan agreement with PSC
pursuant to which we have loaned PSC $10 million.
Emergent believes that the purported termination is invalid and ineffective. Under the terms of
the Agreement, PSC is contractually prohibited from terminating the Agreement if representations
and warranties made by PSC under the Agreement are not true and correct in all material respects or
if PSC is in material breach of covenants required to be performed. It is Emergents position, as
set forth in detail in the complaint in the action pending in the Supreme Court of New York County
captioned Emergent BioSolutions et al. v. Protein Sciences Corporation, et al., Index No.
650221/2008, that PSC has materially breached numerous representations and covenants under the
Agreement and therefore has no right to terminate.
As grounds for its purported termination of the Agreement, PSC has alleged that Emergent has
breached the Agreement by failing to provide additional funding for PSCs continued operations in
excess of the $10 million already loaned to PSC by Emergent and by disclosing confidential information
of PSC in connection with the above-mentioned litigation by Emergent against PSC. It is Emergents
position that neither the Agreement nor the loan agreement requires further funding and that additional discretionary
funding would be inappropriate in light of
fraudulent conduct by PSC and disregard by PSC of its contractual obligations to Emergent. It is also Emergents position that
PSCs allegation that Emergent has disclosed confidential information in violation of the Agreement
is unsupported and inaccurate.
In certain circumstances in connection with a termination of the Agreement, PSC could be entitled
to a termination fee of $1.5 million. However, Emergent does not believe that the circumstances
presented will give rise to payment of any termination fee.